CHICAGO – Eli Lilly and Co’s experimental Alzheimer’s drug slowed cognitive decline by 35% in a closely watched late-stage trial. The drug, donanemab, slowed progression of Alzheimer’s by 35% to 36% compared to a placebo in 1,182 people diagnosed with early-stage disease, Lilly said.